Oncotarget

Mehdi Mollapour, a Professor of Urology, Biochemistry, and Molecular Biology at Upstate Medical University, leads a discussion with colleagues Jennifer Heritz and Sarah Backe on the vital role of molecular chaperones in tumor suppressor stability. They delve into how chaperones like Hsp70 and Hsp90 are crucial in supporting the functionality of these proteins, preventing tumorigenesis. The conversation reveals the significant impact of co-chaperones and discusses the critical gaps in research surrounding these interactions in cancer pathways.

Peter M. Glazer, a Yale University researcher, dives into the future of cancer therapy with his groundbreaking work on the 3E10 antibody. He discusses the evolution of monoclonal antibody therapy, emphasizing their ability to target cancer cells more accurately and reduce side effects. Glazer highlights the challenge of reaching cancer-related molecules inside cells, which his innovative 3E10 aims to overcome. The conversation covers the humanization and modification of antibodies to enhance treatment effectiveness, offering hope for improved cancer therapies.

Explore the fascinating world of Acute Myeloid Leukemia (AML) as researchers dive into how genetic mutations reshape cancer cell behavior. Discover the key role of mutations in growth factor receptors like FLT3 and their impact on treatment resistance. The discussion reveals the intricate rewiring of gene regulatory networks that hampers normal cell differentiation. Listeners will gain insights into the challenges of targeting individual pathways in therapy, emphasizing a multi-omics approach for a deeper understanding of this complex disease.

It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle. Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time. Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy. Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true. Full tribute to Misha: https://www.oncotarget.com/news/pr/tribute-to-dr-mikhail-misha-blagosklonny/

Discover the latest breakthroughs in cancer treatments with revolutionary cell-penetrating antibodies. Learn how a humanized version of the lupus-derived 3E10 antibody is outshining traditional monoclonal therapies. This innovative approach leverages nucleic acid binding for faster cell uptake and enhanced tumor targeting. Plus, find out how this method could lead to more effective strategies for inhibiting RAD51, a key player in cancer progression.

Delve into the fascinating world of molecular chaperones and their pivotal role in tumor suppression. Discover how chaperones like HSP70 and HSP90 safeguard the stability of tumor suppressor proteins. Learn about the crucial interplay between these chaperones and co-chaperones, which is essential for maintaining cellular function. The discussion highlights how disruptions in this delicate balance can lead to cancer progression. Join the researchers as they unveil the complex mechanisms that protect against oncogenic mutations.

Explore the challenges of treating TP53 mutated acute myeloid leukemia, which afflicts 10-15% of cases and shows poor responses to traditional therapies. Discover that allogeneic hematopoietic stem cell transplantation could improve survival rates, particularly when done during complete remission. Dive into research revealing a somber average survival of only 8.5 months without significant differences between treatments, highlighting the transplant's crucial role in managing this difficult condition.

Anna Moore, a researcher from Michigan State University’s Precision Health Program, discusses her groundbreaking work on targeting miR-10b to combat metastatic breast cancer. With a grim survival rate for this advanced stage, Anna highlights how inhibiting miR-10b can significantly impair the stem cell-like traits of cancer cells. She explains the potential of the nanodrug MN-anti in reducing miR-10b expression, suggesting innovative pathways for more effective therapies and a brighter outlook for patients.

Discover the groundbreaking research on the Zika virus as a potential treatment for brain cancer. The discussion reveals how Zika targets glioma stem cells, enhancing traditional therapies and presenting a novel approach to combating glioblastomas. Experts evaluate the promising efficacy and safety from recent studies, suggesting a transformative future for treating CNS tumors. This intriguing exploration offers hope in the fight against one of the most challenging cancers.

Dive into the intricate world of neoadjuvant therapy trials for prostate cancer! Discover the challenges faced in clinical trial design and patient selection. Uncover how the ACDC-RP trial emphasizes maximal androgen blockade to enhance treatment strategies. Insightful discussions reveal the importance of refining approaches in the quest for effective prostate cancer therapies. Tune in for a blend of science and real-world applications!